- The ability to enter key lab test results. Patients or their family member/ carer can record important blood test results such as BCR-ABL PCR, full blood count, kidney function and liver function. Patients can then keep track of their results over time using the tables and graphs in the...
To assess whether the CFs were converting data to the IS reliably, the raw data (%BCR::ABL1/reference gene) from each laboratory were converted to the IS using the newly derived CF for the three test samples. For example, in the 2017 round, 72.3% of results were reported within 2-fold...
The integration of automated magnetic RNA extraction from 2mL of peripheral blood with multiplex real-time PCR for BCR::ABL1 quantification provides a robust, efficient, and economical approach for monitoring CML patients. This optimized method significantly reduces turnaround time, enabling results to ...
Bone marrow (BM) or peripheral blood (PB) samples for clonality analysis were obtained from 23 female patients with CML in CCR or MCR to imatinib. PB or BM from 5 patients without cytogenetic response, 1 patient with active Ph− CML (termed patients in nonresponse [NR]), and from 12 ...
Thus, umbilical cord blood is an alternative stem cell source. However, the yield of stem cells is often limited, and donor lymphocyte infusion (DLI) is usually not possible. Haploidentical stem cell transplantation with post-transplant cyclophosphamide in children and adolescents with high-risk ...
Impact of comorbidities on overall survival in patients with chronic myeloid leukemia: results of the randomized CML Study IV. Blood 2015; 126: 42–49. Article CAS PubMed PubMed Central Google Scholar Swerdlow AJ, Higgins CD, Smith P, Cunningham D, Hancock BW, Horwich A et al. Second ...
Since the high number of CML cells in the blood might have influenced the results, in the pres- ent study, in order to more precisely characterize the immune status in chronic myeloid leukemia (CML), we analyzed both δRec-ψJα sjTRECs and TRBV-BD sjTRECs in sorted CD4+ and CD8+ T...
The BloodCenter of Wisconsin's unique quantitative BCR-ABL1 test did detect this novel breakpoint and was used for monitoring patient response to tyrosine kinase inhibitor (TKI), as shown in Figure. The patient had a gradual response to dasatinib, and on a sample collected a year after the ...
30 A significant proportion of the early progenitor cells in the peripheral blood of CML patients is determined not by normal but by leukemic progenitors, since these have a higher proliferative capacity than normal progenitors.31 Immunophenotypically, the CML blasts can be distinguished from normal ...
Blood 2016; 128: 17–23. demonstrated the potential role of T-cell immunity against CXorf48 antigen in CML patients who achieved TFR and suggested this antigen could be a valuable therapeutic target in CML patients. Promising results for several checkpoint inhibitors have been reported in various...